Dopamine Agonist Treatment of Schizophrenia With N-Propylnorapomorphine

C. A. Tamminga, M. D. Gotts, G. K. Thaker, L. D. Alphs, N. L. Foster

Research output: Contribution to journalArticlepeer-review

50 Scopus citations


We administered N-propylnorapomorphine, a potent aporphine-family dopamine (DA) agonist, to schizophrenic patients with active psychotic symptoms. After acute administration a significant antipsychotic action of N-propylnorapomorphine, maximal at an oral dose of 19 mg, was noted. The antipsychotic action predominated in subjects with neuroleptic-responsive symptoms, not in neuroleptic-nonresponders. However, when N-propylnorapomorphine was administered on a subchronic dosage schedule, no antipsychotic effect occurred. These observations suggest a rapid-onset tolerance phenomenon of psychosis to N-propylnorapomorphine and are consistent with results from preclinical experiments. These data support the idea that the acute antipsychotic response of DA agonists is mediated by the DA autoreceptor but fail to provide evidence for the potential clinical usefulness of this treatment approach.

Original languageEnglish (US)
Pages (from-to)398-402
Number of pages5
JournalArchives of General Psychiatry
Issue number4
StatePublished - Apr 1986

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health


Dive into the research topics of 'Dopamine Agonist Treatment of Schizophrenia With N-Propylnorapomorphine'. Together they form a unique fingerprint.

Cite this